



Noah Voreades Founder & Managing DirectorFounder, GenBiome Consulting

FutureofMicrobiome.co

Microbiome Commercialization Trends - Navigating Increased Competition & 2021 Trends We Got Right

Dec. 2, 9:05 - 9:45 AM ET

C Getter Clearly

Some

Who Is GenBiome Consulting

- 01 Personalized Nutrition
- 02 Microbiome
- 03 Genetic Testing
- 04 CPG + VMS
- 05 Digital Health

GenBiome's unique value proposition is leveraging real-world product development engagements + first principles data-driven insights to support development of products + services that CHANGE ENTIRE CATEGORIES

GenBiome Consulting Focus Areas

CORPORATE DEVELOPMENT

- Business & Strategic Plan Development
- Market Analysis
- Management Consulting

SCIENTIFIC + ANALYTICS Genetic Marker

- Identification & Selection
- Annotation Support
- Bioinformatics
- · Scientific Research & White Papers

MARKETING + BRANDING

- · Channel Strategy
- GTM Strategy
- . Kit Components & Design
- . Report Design + Content Support.





REGULATORY

- Regulatory Strategy * Competitive Intelligence
- Planning + Strategy for Regulatory Meetings
- · Regulatory Documentation Support
- · Regulatory Representation

C Getter Cleaning

2000

Topic Roadmap

- 01 2021 Trends Recap Right vs Wrong
- 02 2022/2023 Trends Consumer, Competition & Consolidation
- Q&A What Trends Are You 03 Seeing & What Might Am I Missing?

2000

01 - 2021 Trends Recap - Right & Wrong

2021 Trend Recap - 5 of 5 Predicted 2021 Trends Realized — Real World Examples Validate Each Trend





PN Inputs

Significant Funding + Low Barriers to Entry + Microbiome's Value



Niche to Mainstream Adoption & Multi-Category Disrupters Taking Market Share



01 Blending of Biotech + Supplements/CPG

Trends in Personalization

Digital Health – Microbiome-Based 03 Competitive or

Evolving Food & 04 Beverage Innovation Reshapes Microbiome & **Adjacent Categories**

05 Featurization of the Microbiome

Trend 1 – Blending of Biotech + Supplements/CPG

Got Right

- √ M&A Increasing 2022/2023 trend
- Rx Failures Increasing JnJ, Finch, Takeda, Seres all had Rx program failures, ceased separate MB Rx business units or collaboration deals - - > driving Rx companies to pivot to consumer or consolidate to survive
- ✓ Rx Leadership Moving to Consumer MB Dirk Gevers becomes CSO of Seed Health & Jonathan Krive fr. AsiaBiome joins Holobiome



✓ **Directionality** – Assumed only MB Rx companies would move consumer - - > Seed is case study w/launch of LUCA Biologics & Sarkis Mazmanian gut-brain-axis collaboration



2021 Slide

20022

C Golfford Lineity

Trend 2 — Increase Focus on Microbiome-Based Personalization Integration

Got Right

- ✓ Personalization Partnerships 2022/2023 trend - -> IFF Health x Salus Optima
- ✓ Personalized MB Test Results Drive Efficacy WellTheory & Digbi Health programs integrates MB testing to support care journey, engagement & behavior modification
- ✓ MB Rx Companies Amassing Novel Datasets— Persephone Biosciences MyBabyBiome project could enable novel infant microbiome personalization tests or products

Got Wrong

✓ DTC Testing Companies Launching MB Tests —
To date none of the leading DTC testing
companies developed MB test



2021 Slide

Country District


Trend 3 – Digital Health Competitive or Complementary

Got Right

- ✓ **Digital Health Increasingly Competitive** Salvo Health, Mahana Therapeutics, Viome, Vivante Health, Digbi Health Function Health continue to compete w/traditional MB testing companies
- ✓ New Entrants Increasing Competition Tiny Health, Evvy & others in stealth mode could be highly disruptive to traditional MB testing companies

Got Wrong

✓ Hope of Traditional MB Testing Companies
Establishing Competitive Moat – To date core
MB testing companies haven't found a way to
develop competitive blocking mechanisms



2021 Slide

C Getterer Leading



Trend 4 — Functional F&B + Non-Traditional Supplement Brands Push Microbiome Into Mainstream

Got Right

- ✓ Food & Beverage Category Driving Growth —
 OLIPOP's functional soda remains fastest growing
 functional beverage despite increased
 competition, BelliWelli IBS bites gain Sprouts
 distribution, Sunday's healthy "Oreo" launches
 signaling intersection of better for you + function
 driving category
- ✓ Powder Supplements Growing Top-tier science is driving growth of microbiome x metabolic health prebiotic fiber companies Supergut & January's Edens



2021 Slide

O Getter Classing



Trend 5 – Featurization of the Microbiome

Got Right

- ✓ Larger Companies Partnering or Acquiring MB Brands 2022/2023 trend w/Microba's recent announcement validating this trend
- ✓ Microbiome Benefits Not Core USP Early stage F&B brands initially positioned products w/MB benefits, but as brand grows this doesn't stay core to consumer messaging...similar trend happening across testing & powder supplements
- ✓ Retail & Digital Health Exploring MB Concepts Stealth companies or projects exploring how MB products or services can support strategic needs

Got Wrong

✓ Hope of Traditional MB Companies Establishing Competitive Moat – To date core MB companies haven't found a way to develop competitive blocking mechanisms



2021 Slide

O Deliver Limits

2000

02 - 2022/2023 Trends - Consumer, Competition & Consolidation

Trend 1 - Increasing M&A + Consolidation + Collaborations

Consumer - M&A





C (Delliow Classifie)

MB Rx - M&A



MB Testing & Services - M&A

165 Acquisition of Quay Pharma WE Further Strengthan Offering

2000

Trend 1 - Increasing M&A + Consolidation + Collaborations

Consumer – Partnerships

Seed Health Launches Gut-Brain Development Program with Axial Therapeutics To Translate Caltech Research into Probiotic

Select, MISS at 1000 OF SELECT

Petro inchestratignation in property



Novozymes and LinusBio explore probletic protection against toxic metals

MB Rx - Partnerships

Enterome signs major strategic R&D collaboration with Nestlé Health Science

Boehringer ingelheim and BiomX Collaborate to Discover IBD Microbiame Biomarkers

Microba Life Sciences Completes Successful IPD & Announces Partnership with Ginkgo Bioworks

Persephone rakes in \$15M to support country's biggest cancer microbiome study

MB Testing -Partnerships

SYNLAB and Microba expand strategic agreement on advanced gut microbiome test

Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences

3 2222

Trend 2 — Increasing Competition in MB Testing — Moving More Clinically Integrated





Trend 3 — B2B Microbiome Ingredient Outlook — Consolidation & Differentiation...But Will Start-Ups Disrupt Encumbents?





Vertically Integrated – Driven by acquisition of Precision Biotics, Microbiome Labs & Biota w/additional partnerships is representing the future of vertically integrated microbiome company



DSM



Personalization & Concierge B2B – IFF acquisition of Health Wright & latest partnership w/Salus Optima to power personalization signals goal of providing customers turnkey holistic wellness platform to drive sales. DSM's funding of Hologram signals similar personalization focus & potential vertical integration






Traditional M&A Ingredient Approach – Both companies take a fairly traditional approach to driving innovation & revenues via M&A. ADM's Mafrig food partnership could enable move into MB F&B categories



Trend 4 — Our Small Intestine is Microbiome's New Hot Spot...Driven by Novel Capsule Technology



Trend 5 – Macro Health & Healthcare Trends Will Exert Largest Influence on Microbiome Category



Contraction to the Contraction of the Contraction o

Trend 5 — Macro Health & Healthcare Trends Will Exert Largest Influence on Microbiome Category



O Gallery Limits



Trend 5 — Macro Health & Healthcare Trends Will Exert Largest Influence on Microbiome Category

Large Affluent Consumer Base Shifting to Wellness + Preventative Care Mindset



Trend 5 — Macro Health & Healthcare Trends Will Exert Largest Influence on Microbiome Category





C Gallery Limits

2000

Trend 5 — Macro Health & Healthcare Trends Will Exert Largest Influence on Microbiome Category

Big Tech| Grocery| Retail Health Need Metabolic Health Sector to Drive Stock
Appreciation

Total FY2021 Revenues


\$1.3T + \$786B + \$448B = \$2.5T

(lig Tech) (Grocery) (Retail Health)

Total FY2021 Revenues

O Golford Smithy

03 - Q&A - What Trends Are You Seeing & What Might Am I Missing?





619-218-1762 genbiome@gmail.com

